HRP20201500T1 - Derivati benzoksazinona za liječenje kožnih oboljenja - Google Patents
Derivati benzoksazinona za liječenje kožnih oboljenja Download PDFInfo
- Publication number
- HRP20201500T1 HRP20201500T1 HRP20201500TT HRP20201500T HRP20201500T1 HR P20201500 T1 HRP20201500 T1 HR P20201500T1 HR P20201500T T HRP20201500T T HR P20201500TT HR P20201500 T HRP20201500 T HR P20201500T HR P20201500 T1 HRP20201500 T1 HR P20201500T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- prophylaxis
- prevention
- skin diseases
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1430003 | 2014-01-23 | ||
| EP15740572.1A EP3097085B1 (en) | 2014-01-23 | 2015-01-22 | Benzoxazinone derivatives for treatment of skin diseases |
| PCT/SE2015/050062 WO2015112081A1 (en) | 2014-01-23 | 2015-01-22 | Benzoxazinone derivatives for treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201500T1 true HRP20201500T1 (hr) | 2020-12-25 |
Family
ID=53681747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201500TT HRP20201500T1 (hr) | 2014-01-23 | 2015-01-22 | Derivati benzoksazinona za liječenje kožnih oboljenja |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9695194B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3097085B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6448651B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106132941B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015209761B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2934025C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123477T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3097085T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2820868T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201500T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE051296T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3097085T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3097085T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3097085T (cg-RX-API-DMAC7.html) |
| RS (1) | RS60830B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3097085T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000557T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112081A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6448651B2 (ja) * | 2014-01-23 | 2019-01-09 | シクセラ ファーマ エービー | 皮膚病の処置のためのベンゾオキサジノン誘導体 |
| KR102579996B1 (ko) * | 2015-05-13 | 2023-09-18 | 니혼노야쿠가부시키가이샤 | 안트라닐산 에스테르 화합물 또는 이의 염류 및 해당 화합물을 함유하는 농원예용 살균제 및 이의 사용 방법 |
| US10821094B2 (en) * | 2016-01-13 | 2020-11-03 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| KR20250070121A (ko) * | 2017-06-16 | 2025-05-20 | 아지트라 인코포레이티드 | Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법 |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| EP3781588B1 (en) | 2018-04-20 | 2024-10-30 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| GB201809378D0 (en) | 2018-06-07 | 2018-07-25 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| JP2022549087A (ja) | 2019-09-18 | 2022-11-24 | ジェネンテック， インコーポレイテッド | 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体および使用方法 |
| CN114615984B (zh) * | 2019-10-01 | 2025-02-07 | 分子皮肤治疗公司 | 作为klk5/7双重抑制剂的苯并噁嗪酮化合物 |
| GB202001447D0 (en) * | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| BR102020009679A2 (pt) | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| TW202304890A (zh) * | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
| JP2024520154A (ja) | 2021-06-01 | 2024-05-21 | シクセラ・ファーマ・アーベー | ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB115399A (en) * | 1917-03-28 | 1918-04-29 | Reginald Guley Lewis | Improved Delivery mechanism for Coin-freed Apparatus and the like. |
| GB1153994A (en) * | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
| WO1999048878A1 (en) * | 1998-03-24 | 1999-09-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| PL1631295T3 (pl) * | 2003-06-06 | 2010-09-30 | Arexis Ab | Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry |
| TWI419884B (zh) | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物 |
| JP6448651B2 (ja) * | 2014-01-23 | 2019-01-09 | シクセラ ファーマ エービー | 皮膚病の処置のためのベンゾオキサジノン誘導体 |
-
2015
- 2015-01-22 JP JP2016544672A patent/JP6448651B2/ja active Active
- 2015-01-22 ES ES15740572T patent/ES2820868T3/es active Active
- 2015-01-22 AU AU2015209761A patent/AU2015209761B2/en active Active
- 2015-01-22 HR HRP20201500TT patent/HRP20201500T1/hr unknown
- 2015-01-22 SI SI201531393T patent/SI3097085T1/sl unknown
- 2015-01-22 EP EP15740572.1A patent/EP3097085B1/en active Active
- 2015-01-22 WO PCT/SE2015/050062 patent/WO2015112081A1/en not_active Ceased
- 2015-01-22 PL PL15740572T patent/PL3097085T3/pl unknown
- 2015-01-22 CA CA2934025A patent/CA2934025C/en active Active
- 2015-01-22 CN CN201580005383.4A patent/CN106132941B/zh active Active
- 2015-01-22 LT LTEP15740572.1T patent/LT3097085T/lt unknown
- 2015-01-22 US US15/113,750 patent/US9695194B2/en active Active
- 2015-01-22 SM SM20200557T patent/SMT202000557T1/it unknown
- 2015-01-22 PT PT157405721T patent/PT3097085T/pt unknown
- 2015-01-22 HU HUE15740572A patent/HUE051296T2/hu unknown
- 2015-01-22 RS RS20201128A patent/RS60830B1/sr unknown
- 2015-01-22 DK DK15740572.1T patent/DK3097085T3/da active
-
2017
- 2017-06-05 US US15/614,462 patent/US10072024B2/en active Active
-
2020
- 2020-10-20 CY CY20201100988T patent/CY1123477T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6448651B2 (ja) | 2019-01-09 |
| CA2934025A1 (en) | 2015-07-30 |
| HUE051296T2 (hu) | 2021-03-01 |
| US10072024B2 (en) | 2018-09-11 |
| ES2820868T3 (es) | 2021-04-22 |
| CN106132941A (zh) | 2016-11-16 |
| JP2017503798A (ja) | 2017-02-02 |
| US20170267692A1 (en) | 2017-09-21 |
| CY1123477T1 (el) | 2022-03-24 |
| EP3097085A4 (en) | 2017-08-09 |
| WO2015112081A1 (en) | 2015-07-30 |
| SMT202000557T1 (it) | 2020-11-10 |
| PL3097085T3 (pl) | 2021-01-11 |
| CN106132941B (zh) | 2018-04-06 |
| RS60830B1 (sr) | 2020-10-30 |
| SI3097085T1 (sl) | 2020-11-30 |
| EP3097085B1 (en) | 2020-07-29 |
| DK3097085T3 (da) | 2020-10-26 |
| CA2934025C (en) | 2022-06-07 |
| PT3097085T (pt) | 2020-10-08 |
| EP3097085A1 (en) | 2016-11-30 |
| LT3097085T (lt) | 2020-10-12 |
| US20170002021A1 (en) | 2017-01-05 |
| AU2015209761A1 (en) | 2016-07-07 |
| US9695194B2 (en) | 2017-07-04 |
| AU2015209761B2 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201500T1 (hr) | Derivati benzoksazinona za liječenje kožnih oboljenja | |
| CY1125318T1 (el) | Τοπικες φαρμακευτικες συνθεσεις | |
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| HRP20190764T1 (hr) | Heterocikli sposobni modulirati odgovore t-stanica, i postupci za njihovu upotrebu | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| MX389958B (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| HRP20191814T1 (hr) | Načini liječenja karcinoma | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| JP2017503798A5 (cg-RX-API-DMAC7.html) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| HRP20171512T1 (hr) | Derivati betulina | |
| BR112017023432A2 (pt) | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo | |
| CR20150432A (es) | Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| HK1231390A1 (zh) | 用於局部给药的药用组合物 | |
| MY183526A (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| HRP20191955T1 (hr) | Orvepitant za liječenje kroničnog pruritusa | |
| WO2015017393A3 (en) | Piperazine derivatives as hiv protease inhibitors | |
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| HK1247837A1 (zh) | 1-甲基-d-色氨酸的盐和前药 | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX373177B (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| WO2015082590A3 (en) | Bis-mmf derivatives | |
| HK1223014A1 (zh) | 用於在预防和/或治疗多动性运动障碍中使用的治疗剂 |